Expertise in
8
conditions

Dr. Hadrien Dulery

Hematology | Oncology
Office
450 Brookline Ave # 548A, 
Boston, MA 
Expertise in
8
conditions
Office
450 Brookline Ave # 548A, 
Boston, MA 

Overview

Hadrien Dulery is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Dulery is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Splenectomy.

He is actively involved in clinical research, co-authoring 138 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
450 Brookline Ave # 548A, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: Axicabtagene Ciloleucel
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 2
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.
Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

138 Total Publications

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.
Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.
Journal: Transplantation and cellular therapy
Published: November 22, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Rachael Grace
Hematology | Oncology
Expertise in
13
conditions
Dr. Rachael Grace
Hematology | Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances

Rachael Grace is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Grace is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Pyruvate Kinase Deficiency, Immune Thrombocytopenic Purpura (ITP), Hemolytic Anemia, Splenectomy, and Gallbladder Removal.

Expertise in
11
conditions
Dr. Steven Dubois
Hematology | Oncology
Expertise in
11
conditions
Dr. Steven Dubois
Hematology | Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma.

Expertise in
14
conditions
Dr. Andrew Yee
Hematology | Oncology
Expertise in
14
conditions
Dr. Andrew Yee
Hematology | Oncology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Yee is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Yee is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Vertebroplasty, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Hadrien Dulery

How do I make an appointment with Dr. Hadrien Dulery?

You can book an appointment with Dr. Hadrien Dulery by calling their office at 857-390-0933. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hadrien Dulery a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hadrien Dulery is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hadrien Dulery specialize in?

While Dr. Hadrien Dulery is a Hematology, they have specific expertise in Bone Marrow Transplant, Graft Versus Host Disease (GvHD), and Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Hadrien Dulery participate in research or clinical trials?

Yes. Dr. Hadrien Dulery has published 138 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Dr. Hadrien Dulery's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dulery's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile